A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs

References

• Vinding G, Miller I, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population‐based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170(4):884–889.
   PubMed Web of Science ®Google Scholar
• Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412–419.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2):191–194.
   PubMed Web of Science ®Google Scholar
• Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596–601.
   PubMed Web of Science ®Google Scholar
• Von Der Werth J, Williams H. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14(5):389–392.
   PubMed Web of Science ®Google Scholar
• Wang B, Yang W, Wen W, et al. γ-secretase gene mutations in familial acne inversa. Science. 2010;330(6007):1065.
   PubMed Web of Science ®Google Scholar
• Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97–103.
   PubMed Web of Science ®Google Scholar
• Gauntner TD. Hormonal, stem cell and notch signalling as possible mechanisms of disease in hidradenitis suppurativa: a systems‐level transcriptomic analysis. Br J Dermatol. 2019;180(4):203–204.
   PubMed Web of Science ®Google Scholar
• Guet-Revillet H, Jais J-P, Ungeheuer M-N, et al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study. Clinl Infect Dis. 2017;65:282–291.
   PubMed Web of Science ®Google Scholar
• Hurley H. Dermatologic surgery, principles and practice. New York: Marcel; 1989.
   Google Scholar
• Kimball A, Sobell J, Zouboulis C, et al. HiSCR (Hidradenitis Suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–994.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211–213.
   PubMed Web of Science ®Google Scholar
• Zouboulis C, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa severity score system (IHS 4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–1409.
   PubMed Web of Science ®Google Scholar
• Kimball A, Jemec G, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa clinical response (Hi SCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434–1442.
   PubMed Web of Science ®Google Scholar
• Humira (adalimumab) injection for subcutaneous use. Chicago (IL): AbbVie, Inc; [ cited 2020 December 19]. Updated March 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s415lbl.pdf.
   Google Scholar
• Matusiak Ł, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-α in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-α agents? Acta Derm Venereol. 2009;89(6):601–603.
   PubMed Web of Science ®Google Scholar
• Van Der Zee H, De Ruiter L, Van Den Broecke D, et al. Elevated levels of tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β and IL‐10 in hidradenitis suppurativa skin: a rationale for targeting TNF‐α and IL‐1β. Br J Dermatol. 2011;164(6):1292–1298.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434.
   PubMed Web of Science ®Google Scholar
• Amano M, Grant A, Kerdel FA. A prospective open‐label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49(8):950–955.
   PubMed Web of Science ®Google Scholar
• Christina Goussi M, Aimilios Lallas M, Eleni Chovarda M, et al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. 2012;11(5 Suppl):s15–s20.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Kerdel F, Adams D, van der Zee HH, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–855.
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard C, Lophaven S, et al. A double‐blind placebo‐controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–398.
   PubMed Web of Science ®Google Scholar
• Morita A, Takahashi H, Ozawa K, et al. Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa. J Dermatol. 2019;46(9):745–751.
   PubMed Web of Science ®Google Scholar
• Nader A, Beck D, Noertersheuser P, et al. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56(9):1091–1102.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):e62.
   Web of Science ®Google Scholar
• Morita A, Takahashi H, Ozawa K, et al. Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: open‐label phase 3 results. J Dermatol. 2021;48(1):3–13.
   PubMed Web of Science ®Google Scholar
• Tzanetakou V, Stergianou D, Giamarellos-Bourboulis EJ. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. Expert Opin Drug Saf. 2020;19(4):381–393.
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Trigoni A, Galanis N, et al. Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: real life data. Dermatol Reports. 2018;10(2):10.
   Web of Science ®Google Scholar
• Blanco R, Martínez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145(5):580–584.
   PubMedGoogle Scholar
• Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long‐term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49(12):1445–1449.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Gordon KB, Rosenbaum JT, et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2020;37(1):364–380.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31(11):1853–1859.
   PubMed Web of Science ®Google Scholar
• Pena ZG, Sivamani RK, Konia TH, et al. Squamous cell carcinoma in the setting of chronic hidradenitis suppurativa; report of a patient and update of the literature. Dermatol Online J. 2015;21(4):21.
   Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Gold DA, Reeder VJ, Mahan MG, et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(4):699–703.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072.
   PubMed Web of Science ®Google Scholar
• Marzano A, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study. Br J Dermatol. 2021;184(1):133–140.
   PubMed Web of Science ®Google Scholar
• Ghias MH, Johnston AD, Kutner AJ, et al. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094–1101.
   PubMed Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–217.
   PubMed Web of Science ®Google Scholar
• Mekkes J, Bos J. Long‐term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158(2):370–374.
   PubMed Web of Science ®Google Scholar
• Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702–708.
   PubMed Web of Science ®Google Scholar
• Remicade (infliximab) for injection, for intravenous use. Janssen Biotech, Inc. [ cited 2020 Dec 31]. Updated May 2020.
   Google Scholar
• French JB, Bonacini M, Ghabril M, et al. Hepatotoxicity associated with the use of anti-TNF-α agents. Drug Saf. 2016;39(3):199–208.
   PubMed Web of Science ®Google Scholar
• Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther. 2006;6(8):797–805.
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315–1324.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969.
   PubMed Web of Science ®Google Scholar
• Menter A, Reich K, Gottlieb AB, et al. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol. 2008;7(12):1137–1146.
   PubMedGoogle Scholar
• Dinarello CA. Blocking interleukin‐1β in acute and chronic autoinflammatory diseases. J Intern Med. 2011;269(1):16–28.
   PubMed Web of Science ®Google Scholar
• Kineret (anakinra) injection, for subcutaneous use. Amgen, Inc. [ cited 2020 Jan 8]. Updated May 2016.
   Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52–59.
   PubMed Web of Science ®Google Scholar
• Leslie KS, Tripathi SV, Nguyen TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(2):243–251.
   PubMed Web of Science ®Google Scholar
• André R, Marescassier H, Gabay C, et al. Long‐term therapy with anakinra in hidradenitis suppurativa in three patients. Int J Dermatol. 2019;58(11):e208–e209.
   PubMed Web of Science ®Google Scholar
• Stelara (ustekinumab) injection, for subcutaneous or intravenous use. Janssen Biotech, Inc. [ cited 2021 Jan 9]. Updated October 2019.
   Google Scholar
• Blok J, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839–846.
   PubMed Web of Science ®Google Scholar
• Papp K, Griffiths C, Gordon K, et al. Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up. Br J Dermatol. 2013;168(4):844–854.
   PubMed Web of Science ®Google Scholar
• Cosentyx (secukinumab) injection, for subcutaneous use. Novartis, Inc. [ cited 2021 Jan 8]. Updated January 2020.
   Google Scholar
• Ling Y, Puel A. IL-17 and infections. Actas dermo-sifiliograficas. 2014;105:34–40.
   PubMedGoogle Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):e84.
   Web of Science ®Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609–611.
   PubMed Web of Science ®Google Scholar
• Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate‐severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting. J Eur Acad Dermatol Venereol. 2021. DOI:https://doi.org/10.1111/jdv.17178
   Google Scholar
• ClinicalTrials.gov. Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimes of Secukinumab in subjects with Hidradenitis Suppurativa. Identifier: NCT04179175.
   Google Scholar
• ClinicalTrials.gov. Study of efficacy and safety of two Secukinumab dose regimens in subjects with moderate to severe Hidradenitis Suppurativa (HS) (SUNRISE). Identifier: NCT03713632.
   Google Scholar
• Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413–1420.
   PubMed Web of Science ®Google Scholar
• Tremfya (guselkumab) injection for subcutaneous use. Janssen Biotech, Inc; [ cited 2020 December 31]. Updated July 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf.
   Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of guselkumab for the treatment of participants with moderate to severe hidradenitis suppurativa (HS) (NOVA). Identifier NCT03628924.
   Google Scholar
• ClinicalTrials.gov. Guselkumab for hidradenitis suppurativa, a mode of action study (HiGUS). Identifier NCT04061395.
   Google Scholar
• ClinicalTrials.gov. Biomarkers in participants with hidradenitis suppurativa receiving guselkumab. Identifier NCT04084665.
   Google Scholar
• Casseres RG, Kahn JS, Her MJ, et al. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. 2019;81(1):265–267.
   PubMed Web of Science ®Google Scholar
• Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33(3):e140–e141.
   PubMed Web of Science ®Google Scholar
• Reich K, Griffiths CE, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–945.
   PubMed Web of Science ®Google Scholar
• Micu MC, Micu R, Surd S, et al. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology. 2014;53(7):1250–1255.
   PubMed Web of Science ®Google Scholar
• Winger EE, Reed JL, Ashoush S, et al. Degree of TNF‐α/IL‐10 cytokine elevation correlates with IVF success rates in women undergoing treatment with adalimumab (Humira) and IVIG. Am J Reprod Immunol. 2011;65(6):610–618.
   PubMed Web of Science ®Google Scholar
• Winger EE, Reed JL, Ashoush S, et al. Treatment with adalimumab (Humira®) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2009;61(2):113–120.
   PubMed Web of Science ®Google Scholar
• Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248–255.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–119.
   PubMed Web of Science ®Google Scholar
• Weber‐Schoendorfer C, Oppermann M, Wacker E, centres noFp, Beghin D, Cuppers‐Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, et al. Pregnancy outcome after TNF‐α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80(4):727–739.
   PubMed Web of Science ®Google Scholar
• Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13(12):1699–1708.
   PubMed Web of Science ®Google Scholar
• Alsenaid A, Prinz J. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016;30(3):488–490.
   PubMed Web of Science ®Google Scholar
• Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11(10):1240.
   PubMed Web of Science ®Google Scholar
• Watson N, Wu K, Farr P, et al. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. Br J Dermatol. 2019;180(1):195–196.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, et al. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient. Dermatol Ther. 2019;32(3):e12895.
   PubMed Web of Science ®Google Scholar
• Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohn’s Colitis. 2018;12(3):376–378.
   Google Scholar
• Youngstein T, Hoffmann P, Gül A, et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology. 2017;56(12):2102–2108.
   PubMed Web of Science ®Google Scholar
• Smith CJ, Chambers CD. Five successful pregnancies with antenatal anakinra exposure. Rheumatology. 2018;57(7):1271–1275.
   PubMed Web of Science ®Google Scholar
• Warren R, Reich K, Langley R, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205.
   PubMed Web of Science ®Google Scholar
• Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Women’s Health. 2010;2:199.
   PubMedGoogle Scholar
• Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108(9):1426–1438.
   PubMed Web of Science ®Google Scholar
• Matro R, Martin CF, Wolf D, et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155(3):696–704.
   PubMed Web of Science ®Google Scholar
• Bi Y, Liu J, Wang J, et al. Model-informed drug development approach supporting approval of adalimumab (HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective. AAPS J. 2019;21(5):91.
   PubMed Web of Science ®Google Scholar
• Kim SR, Kibbi N, Craiglow BG. Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient. JAAD Case Rep. 2019;5(6):552–554.
   PubMedGoogle Scholar
• Köstner K, Prelog M, Almanzar G, et al. Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist. Rheumatology. 2018;57(5):936–938.
   PubMed Web of Science ®Google Scholar
• Wells LE, Evans T, Hilton R, et al. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. Pediatr Dermatol. 2019;36(3):384–385.
   PubMed Web of Science ®Google Scholar
• Gallitano SM, McDermott L, Brar K, et al. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74(5):974–980.
   PubMed Web of Science ®Google Scholar
• Bartos G, Cline A, Beroukhim K, et al. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018;24(11):24.
   Google Scholar
• Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Deutschen Dermatologischen Gesellschaft= J Ger Soc Dermatol: JDDG. 2019;17:646.
   Web of Science ®Google Scholar
• Paparizos V, Rallis E, Kirsten L, et al. Ustekinumab for the treatment of HIV psoriasis. J Dermatological Treat. 2012;23(6):398–399.
   PubMed Web of Science ®Google Scholar
• Saeki H, Ito T, Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015;29(8):1653–1655.
   PubMed Web of Science ®Google Scholar
• Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168(3):609–616.
   PubMed Web of Science ®Google Scholar
• Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90(6):359–371.
   PubMed Web of Science ®Google Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):e85.
   PubMed Web of Science ®Google Scholar
• Siegel S, Winthrop K, Ehst B, et al. Ustekinumab use in patients with severe psoriasis co‐infected with hepatitis B and/or C. Br J Dermatol. 2019;180(5):1232–1233.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Fukae J, Fukaya S, et al. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs. Int J Rheum Dis. 2019;22(4):574–582.
   PubMed Web of Science ®Google Scholar
• Bevans S, Mayo T, Elewski B. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol JEADV. 2018;32(3):e120.
   PubMed Web of Science ®Google Scholar
• Feaster B, Cline A, Feldman SR. Secukinumab for psoriasis in a patient with hepatitis B. Dermatol Online J. 2018;24(9):24.
   Google Scholar
• Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169(6):1295–1303.
   PubMed Web of Science ®Google Scholar
• Peccerillo F, Odorici G, Pellacani G, et al. Secukinumab: a positive outcome in a patient with severe psoriasis and HBV‐HCV co‐infection. Dermatol Ther. 2018;31(4):e12601.
   PubMed Web of Science ®Google Scholar
• Yanagihara S, Sugita K, Yoshida Y, et al. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol. 2017;27(2):185–186.
   PubMed Web of Science ®Google Scholar
• Ting S-W, Chen Y-C, Huang Y-H, et al. Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab. Clin Drug Investig. 2018;38(9):873–880.
   PubMed Web of Science ®Google Scholar
• Chiu H-Y, Chung-Yee Hui R, Huang Y-H, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829–834.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Zaza G, Del Giglio M, et al. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. J Am Acad Dermatol. 2020;83(1):285–287.
   PubMed Web of Science ®Google Scholar
• Holcomb ZE, Santillan MR, Morss-Walton PC, et al. Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. J Am Acad Dermatol. 2020;83(4):1215–1218.
   PubMed Web of Science ®Google Scholar
• Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. 2020;383(1):85–88.
   Web of Science ®Google Scholar
• Maghfour J, Elliott E, Gill F, et al. Effect of biologic drugs on renal function in psoriasis patients with chronic kidney disease. J Am Acad Dermatol. 2020;82(5):1249–1251.
   PubMed Web of Science ®Google Scholar
• Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341–1348.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy and safety of Bimekizumab in study participants with moderate to severe Hidradenitis Suppurativa (BE HEARD I). Identifier: NCT04242446.
   Google Scholar
• ClinicalTrials.gov. Treatment of moderate Hidradenitis Suppurativa. Identifier: NCT03910803.
   Google Scholar
• ClinicalTrials.gov. Efficacy, safety, and pharmacokinetics study of CJM112 in Hidradenitis Suppurativa patients. Identifier: NCT02421172.
   Google Scholar
• Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656–666.
   PubMed Web of Science ®Google Scholar
• Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138(4):795–801.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Natsis NE, Kerdel F, et al. A phase II open-label study of Bermekimab in patients with Hidradenitis Suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020;140(8):1538–1545.e2.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of Bermekimab in patients with Hidradenitis Suppurativa. Identifier NCT04019041.
   Google Scholar
• ClinicalTrials.gov. A global study comparing Risankizumab to Placebo in adult participants with moderate to severe Hidradenitis Suppurativa (DETERMINED 1). Identifier: NCT03926169.
   Google Scholar
• ClinicalTrials.gov. A study of oral Upadacitinib tablet compared to Placebo in adult participants with moderate to severe Hidradenitis Suppurativa to assess change in disease symptoms. Identifier: NCT04430855.
   Google Scholar
• ClinicalTrials.gov. A study to evaluate the safety and efficacy of PF-06650833, PF-06700841, and PF 06826647 in adults with Hidradenitis Suppurativa. Identifier: NCT04092452.
   Google Scholar
• ClinicalTrials.gov. A Placebo-controlled study of the safety of INCB054707 in participants with Hidradenitis Suppurativa. Identifier: NCT03607487.
   Google Scholar
• ClinicalTrials.gov. Study of efficacy and safety of investigational treatments in patients with moderate to severe Hidradenitis Suppurativa. Identifier: NCT03827798.
   Google Scholar
• ClinicalTrials.gov. Evaluation of safety and efficacy of Avacopan in subjects with moderate to severe Hidradenitis Suppurativa (AURORA). Identifier: NCT03852472.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety study of IFX-1 in patients with moderate to severe Hidradenitis Suppurativa (HS) (SHINE). Identifier: NCT03487276.
   Google Scholar
• ClinicalTrials.gov. A study of LY3041658 in adults with Hidradenitis Suppurativa. Identifier: NCT04493502.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety of Efalizumab in the treatment of moderate-severe Hydradenitis Suppurativa. Identifier: NCT00134134.
   Google Scholar
• ClinicalTrials.gov. Safety and Pharmacokinetics of repeat doses of CSL324 in subjects with Hidradenitis Suppurativa and Palmoplantar Pustulosis. Identifier: NCT03972280.
   Google Scholar